logo

FOREST LAB(NYSE:FRX)
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician''s prescription, as well as non-prescription pharmaceuticalproducts sold over-the-counter. Forest''s most important United Statesproducts consist of branded ethical drug specialties marketed directly, or to physicians by the company''s Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales salesforces.
# Employees: 5225
Address: 909 Third Avenue,New York,NY,USA
Phone: 212-421-7850
Fax: 212-750-9152
Website: www.frx.com
Email: Investor.Relations@frx.com
Sector: Medical
Industry: MED-DRUGS
Executive Officers
Howard Solomon (Chmn.; C.E.O.; Dir.)
Lawrence S. Olanoff (Presi.; C.O.O.; Dir.)
Francis I. Perier Jr. (Sr. V.P.; Fin.; C.F.O.)
William J. Candee III (Dir.)
George S. Cohan (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 1/19/2010
Mean EPS (Next Qtr): $0.86
Mean EPS (Year): $3.46
Mean Estimate(Long Term): $4.83
P/E Ratio(Based on EPS estimate): 8.550
Number of Estimates: 24
Shares Performance
Period FRX Compare to S&P
YTD 16.10 % -3.92 %
4 Weeks 6.06 % 4.92 %
12 Weeks 1.58 % -4.23 %
Shares Information
Analyst Coverage: Y
Avg Volume: 2709391
Shares Outstanding: 301M
Market Cap: $8.92B
52 Week High: $30.25
52 Week Low: $18.79
P/E Ratio: 8.420
PEG Ratio: 1.770
Split: On 1/9/2003 FRX split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -2.30 %
EPS Growth in Last Year: 6.25 %
Sales Growth in Last Quarter: 5.53 %
Sales Growth in Last Quarter: 7.20 %
Financials
Qtr Book Value: $1.93
Cash Flow/Share: $7.77
Change in Payout Ratio: 0.000
Price/Sales: 2.210
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia